Very few circulating biomarkers apart from glycated Hb (HbA1c) and advanced glycation endproducts (AGE) [43] can help stratify T2D patients at risk of microvascular injury in clinical practice. This evidence concerns the gene GSTM1 and type 2 diabetes mellitus.